In This Section

AACR Virtual Meeting: Myeloma: Discovery to Therapy

April 26-27, 2021
Virtual Meeting

Register Now

Conference Cochairs

Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts
Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Massachusetts

Myeloma is the second most common blood cancer diagnosis in the United States, with an estimated 32,270 new cases in 2020. Patient outcomes have improved over the last few years due to the development and FDA approval of novel therapeutics. New therapeutic options remain a priority to counter a lack of response to treatment and treatment resistance or relapse.

This virtual meeting will be the first AACR conference focused on myeloma and will discuss the genomics and epigenetics of myeloma, disease progression, and treatment options in hopes of improving clinical outcomes. Sessions will feature talks from leaders in the field and extended panel discussions.

Attendee registration includes access to all sessions presented during the live April 26-27, 2021, program and to the on-demand recordings. On-demand materials will be available for 90 days starting approximately 5-7 business days after the live program ends.

Professional Educational Grants

GlaxoSmithKline
Pfizer


Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available

*Artwork from Chesi M et al. Monosomic loss of MIR15A/MIR16-1 Is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov 2020;1:68–81. Read the full article here.

This image has an empty alt attribute; its file name is Twitter-bird-blue-on-white_50x50.jpg


#AACRMDT21